Santen Receives UK Approval for Ryjunea® (low-dose atropine 0.1 mg/ml) to Slow Progression of Childhood Myopia

Contributed by: PR Newswire

Tags

SANTEN-MHRA-APPROVAL

More Like This

Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

PR Newswire associated0

New Ipsos global survey shines a light on the myopia epidemic

PR Newswire associated0

HOYA Vision Care Releases One-Year MiYOSMART European Study Results

HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting

PR Newswire associated0

CooperVision to Launch MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses

NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

PR Newswire associated0

Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland

Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)